drugset / Trial / NCT01793883
Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza
Phase 2
Completed
639 enrolled
Biota Scientific Management Pty Ltd
Department of Health and Human Services · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This Phase 2 protocol is designed to compare two dose levels of laninamivir octanoate versus placebo. The objectives are to obtain safety and efficacy in adults aged 18 to 64 years who present to clinic with symptomatic presumptive influenza A or B infection.
Timeline
- Start
- 2013-05
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Laninamivir Octanoate | Small molecule | 40 mg | Inhaled |
| Comparator | Laninamivir Octanoate | Small molecule | 80 mg | Inhaled |